Phase 1 data are positive but early; the modest response rate limits immediate stock catalyst. Monitor for Phase 2 top-line results in cholangiocarcinoma (expected in 2027). No change to fundamental outlook.
Price Chart
Executive Summary
Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. The data show a favorable safety profile and proof-of-mechanism, but clinical activity was modest with one partial response among 46 patients. An investigator-initiated Phase 2 trial in cholangiocarcinoma is enrolling.
Key Facts
- Phase 1 data published in Nature Cancer show MP0317 activates CD40 locally in tumors with favorable safety.
- One unconfirmed partial response and 14 stable disease observed in 46 patients with advanced solid tumors.
- Phase 2 investigator-initiated trial in front-line cholangiocarcinoma open with patient dosing ongoing.
- Pharmacokinetics support weekly or every-three-week dosing; combination with checkpoint inhibitors is being explored.
Financial Impact
No financial data disclosed; early-stage clinical program with no near-term revenue impact.
Risk Factors
- Phase 2 trial may fail to show improved progression-free survival.
- Competition from other CD40 agonists and immune therapies.
- Company has no approved products and relies on financing for operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285827 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers